Background: Cardiovascular disease caused by atherosclerosis is responsible for 18 million deaths annually, highlighting a significant need for new medical therapies, especially for patients who are ...
A novel once-daily oral PCSK9 inhibitor lowered LDL by up to 60% at 24 weeks in patients with heart disease or at high risk ...
When compared to published data with inclisiran, a small interfering RNA (siRNA) molecule that inhibits production of the PCSK9 enzyme, the data showed lipid lowering for LDL-C, non-HDL-C, ApoB, and ...
Over a century of epidemiologic studies and randomized trials have definitively established the causal role of cholesterol in the development of atherosclerosis. Total cholesterol, and later ...
Northwestern University researchers have identified structural features in engineered cell receptors that correlate with ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
MILAN, Italy—Obicetrapib, an investigational agent belonging to a drug class that has been largely dismissed by cardiovascular researchers, can reduce LDL-cholesterol levels when added to ...
High levels of low-density lipoprotein (LDL) cholesterol can cause artery blockages and diseases like heart attacks and strokes. Further, it raises the risk of cardiovascular disease (CVD). Thickened ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback